Biotech layoffs, slumping stocks, and a 2024 preview
This week on "The Readout LOUD" podcast: Why are rich biotechs cutting costs? Has #JPM24 already worn off? And what's going to move markets in 2024?
Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
What's Your Reaction?
